B-cell acute lymphoblastic leukemia, pediatric, Ph-positive

Back to Top
This page contains studies that were specific to pediatric populations. For the more general pediatric B-ALL page, follow this link. For the more general Ph+ B-ALL page, follow this link.
Last updated on 2024-07-23:7 regimens on this page
7 variants on this page
=Guidelines=
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
==NCCN==
*NCCN does not currently have guidelines at this granular level; please see NCCN Guidelines - Pediatric Acute Lymphoblastic Leukemia.
=Upfront therapy=
==COG AALL1122 protocol==
Study 	Dates of enrollment 	Evidence
Hunger et al. 2023 (COG AALL1122)	2012-03-13 to 2014-05-27	Phase 2 (RT)
===Induction, 1A===
Note: Per the protocol, "All patients will receive Induction 1A as per institutional standard of care." Only the details for dasatinib are provided.
====Targeted therapy====
*Dasatinib (Sprycel) 60 mg/m2 PO once per day on days 15 to 33
33-day course, followed immediately by:
===Induction, 1B===
====Chemotherapy====
*Cyclophosphamide (Cytoxan) 1000 mg/m2 IV once per day on days 1 & 28
*Mercaptopurine (6-MP) 60 mg/m2 PO once per day on days 1 to 28
*Cytarabine (Ara-C) 75 mg/m2 IV or SC once per day on days 3 to 6, 10 to 13, 17 to 20, 24 to 27
====Targeted therapy====
*Dasatinib (Sprycel) 60 mg/m2 PO once per day
====CNS therapy, prophylaxis====
*Methotrexate (MTX) IT once per day on days 3 & 17
6- to 8-week course, including 2 to 4 weeks of recovery period, followed by:
===Consolidation, Block 1===
====Chemotherapy====
To be completed
===References===
# COG AALL1122: Hunger SP, Tran TH, Saha V, Devidas M, Valsecchi MG, Gastier-Foster JM, Cazzaniga G, Reshmi SC, Borowitz MJ, Moorman AV, Heerema NA, Carroll AJ, Martin-Regueira P, Loh ML, Raetz EA, Schultz KR, Slayton WB, Cario G, Schrappe M, Silverman LB, Biondi A. Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2023 Jul;10(7):e510-e520. link to original article contains partial dosing details in supplement EuroPMC NCT01460160
=Upfront induction therapy=
==Daunorubicin, Pegaspargase, Vincristine, Prednisone, Dasatinib==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Shen et al. 2020 (CCCG-ALL-2015-Ph)	2015-2018 	Phase 3 (E-switch-ic)	Daunorubicin, Pegaspargase, Vincristine, Prednisone, Imatinib	Longer EFS (primary endpoint)
Note: The schedule as reported begins after the 4-day pre-phase was completed; the exact start day of dasatinib was not specified. Pegaspargase was specified as being given for 1 dose, but also specified to be given on 2 days during induction.
====Preceding treatment====
*Dexamethasone pre-phase
====Chemotherapy====
*Daunorubicin (Cerubidine) 25 mg/m2 IV once per day on days 5 & 12
*Pegaspargase (Oncaspar) 2000 units/m2 IM once per day on days 6 & 26
*Vincristine (Oncovin) 1.5 mg/m2 (maximum dose of 2 mg) IV once per day on days 5, 12, 19, 26
====Glucocorticoid therapy====
*Prednisone (Sterapred) 15 mg/m2 PO three times per day on days 5 to 28
====Targeted therapy====
*Dasatinib (Sprycel) 80 mg/m2/day PO
28-day course
====Subsequent treatment====
*Induction II; see paper for details
===References===
# CCCG-ALL-2015-Ph: Shen S, Chen X, Cai J, Yu J, Gao J, Hu S, Zhai X, Liang C, Ju X, Jiang H, Jin R, Wu X, Wang N, Tian X, Pan K, Jiang H, Sun L, Fang Y, Li CK, Hu Q, Yang M, Zhu Y, Zhang H, Li C, Pei D, Jeha S, Yang JJ, Cheng C, Tang J, Zhu X, Pui CH. Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA Oncol. 2020 Mar 1;6(3):358-366. Epub 2020 Jan 16. link to original article link to PMC article dosing details in supplement have been reviewed by our editors EuroPMC ChiCTR-IPR-14005706
==Daunorubicin, Pegaspargase, Vincristine, Prednisone, Imatinib==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Shen et al. 2020 (CCCG-ALL-2015-Ph)	2015-2018 	Phase 3 (C)	Daunorubicin, Pegaspargase, Vincristine, Prednisone, Dasatinib	Shorter EFS
Note: The schedule as reported begins after the 4-day pre-phase was completed; the exact start day of imatinib was not specified. Pegaspargase was specified as being given for 1 dose, but also specified to be given on 2 days during induction.
====Preceding treatment====
*Dexamethasone pre-phase
====Chemotherapy====
*Daunorubicin (Cerubidine) 25 mg/m2 IV once per day on days 5 & 12
*Pegaspargase (Oncaspar) 2000 units/m2 IM once per day on days 6 & 26
*Vincristine (Oncovin) 1.5 mg/m2 (maximum dose of 2 mg) IV once per day on days 5, 12, 19, 26
====Glucocorticoid therapy====
*Prednisone (Sterapred) 15 mg/m2 PO three times per day on days 5 to 28
====Targeted therapy====
*Imatinib (Gleevec) 300 mg/m2/day PO
28-day course
====Subsequent treatment====
*Induction II; see paper for details
===References===
# CCCG-ALL-2015-Ph: Shen S, Chen X, Cai J, Yu J, Gao J, Hu S, Zhai X, Liang C, Ju X, Jiang H, Jin R, Wu X, Wang N, Tian X, Pan K, Jiang H, Sun L, Fang Y, Li CK, Hu Q, Yang M, Zhu Y, Zhang H, Li C, Pei D, Jeha S, Yang JJ, Cheng C, Tang J, Zhu X, Pui CH. Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA Oncol. 2020 Mar 1;6(3):358-366. Epub 2020 Jan 16. link to original article link to PMC article dosing details in supplement have been reviewed by our editors EuroPMC ChiCTR-IPR-14005706
=Upfront induction therapy=
==Daunorubicin, Pegaspargase, Vincristine, Prednisone, Dasatinib==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Shen et al. 2020 (CCCG-ALL-2015-Ph)	2015-2018 	Phase 3 (E-switch-ic)	Daunorubicin, Pegaspargase, Vincristine, Prednisone, Imatinib	Longer EFS (primary endpoint)
Note: The schedule as reported begins after the 4-day pre-phase was completed; the exact start day of dasatinib was not specified. Pegaspargase was specified as being given for 1 dose, but also specified to be given on 2 days during induction.
====Preceding treatment====
*Dexamethasone pre-phase
====Chemotherapy====
*Daunorubicin (Cerubidine) 25 mg/m2 IV once per day on days 5 & 12
*Pegaspargase (Oncaspar) 2000 units/m2 IM once per day on days 6 & 26
*Vincristine (Oncovin) 1.5 mg/m2 (maximum dose of 2 mg) IV once per day on days 5, 12, 19, 26
====Glucocorticoid therapy====
*Prednisone (Sterapred) 15 mg/m2 PO three times per day on days 5 to 28
====Targeted therapy====
*Dasatinib (Sprycel) 80 mg/m2/day PO
28-day course
====Subsequent treatment====
*Induction II; see paper for details
===References===
# CCCG-ALL-2015-Ph: Shen S, Chen X, Cai J, Yu J, Gao J, Hu S, Zhai X, Liang C, Ju X, Jiang H, Jin R, Wu X, Wang N, Tian X, Pan K, Jiang H, Sun L, Fang Y, Li CK, Hu Q, Yang M, Zhu Y, Zhang H, Li C, Pei D, Jeha S, Yang JJ, Cheng C, Tang J, Zhu X, Pui CH. Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA Oncol. 2020 Mar 1;6(3):358-366. Epub 2020 Jan 16. link to original article link to PMC article dosing details in supplement have been reviewed by our editors EuroPMC ChiCTR-IPR-14005706
==Daunorubicin, Pegaspargase, Vincristine, Prednisone, Imatinib==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Shen et al. 2020 (CCCG-ALL-2015-Ph)	2015-2018 	Phase 3 (C)	Daunorubicin, Pegaspargase, Vincristine, Prednisone, Dasatinib	Shorter EFS
Note: The schedule as reported begins after the 4-day pre-phase was completed; the exact start day of imatinib was not specified. Pegaspargase was specified as being given for 1 dose, but also specified to be given on 2 days during induction.
====Preceding treatment====
*Dexamethasone pre-phase
====Chemotherapy====
*Daunorubicin (Cerubidine) 25 mg/m2 IV once per day on days 5 & 12
*Pegaspargase (Oncaspar) 2000 units/m2 IM once per day on days 6 & 26
*Vincristine (Oncovin) 1.5 mg/m2 (maximum dose of 2 mg) IV once per day on days 5, 12, 19, 26
====Glucocorticoid therapy====
*Prednisone (Sterapred) 15 mg/m2 PO three times per day on days 5 to 28
====Targeted therapy====
*Imatinib (Gleevec) 300 mg/m2/day PO
28-day course
====Subsequent treatment====
*Induction II; see paper for details
===References===
# CCCG-ALL-2015-Ph: Shen S, Chen X, Cai J, Yu J, Gao J, Hu S, Zhai X, Liang C, Ju X, Jiang H, Jin R, Wu X, Wang N, Tian X, Pan K, Jiang H, Sun L, Fang Y, Li CK, Hu Q, Yang M, Zhu Y, Zhang H, Li C, Pei D, Jeha S, Yang JJ, Cheng C, Tang J, Zhu X, Pui CH. Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA Oncol. 2020 Mar 1;6(3):358-366. Epub 2020 Jan 16. link to original article link to PMC article dosing details in supplement have been reviewed by our editors EuroPMC ChiCTR-IPR-14005706
=Consolidation after upfront therapy (including post-remission therapy)=
Note that many of these regimens are complex and as such will be referred to by their study name, not by the individual drug names. This is also a phase of treatment often referred to as post-remission or postinduction therapy.
==Etoposide, Ifosfamide, Imatinib==
===Regimen===
Study 	Dates of enrollment	Evidence
Schultz et al. 2009 (COG AALL0031)	2002-2006 	Phase 2 (RT)
Note: the schedule is not specified for etoposide and ifosfamide, and the filgrastim dose is erroneous within the manuscript.
====Preceding treatment====
*Induction (see paper for details)
====Chemotherapy====
*Etoposide (Vepesid) 100 mg/m2 IV (schedule not specified)
*Ifosfamide (Ifex) 3400 mg/m2 IV (schedule not specified)
====Targeted therapy====
*Imatinib (Gleevec) 340 mg/m2 PO once per day
====Supportive therapy====
*Filgrastim (Neupogen) 5 mcg/kg SC once per day on days 6 to 15
21-day course
====Subsequent treatment====
*Consolidation block 2 (see paper for details)
===References===
# COG AALL0031: Schultz KR, Bowman WP, Aledo A, Slayton WB, Sather H, Devidas M, Wang C, Davies SM, Gaynon PS, Trigg M, Rutledge R, Burden L, Jorstad D, Carroll A, Heerema NA, Winick N, Borowitz MJ, Hunger SP, Carroll WL, Camitta B. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a Children's Oncology Group study. J Clin Oncol. 2009 Nov 1;27(31):5175-81. Epub 2009 Oct 5. link to original article link to PMC article EuroPMC NCT00022737
## Update: Schultz KR, Carroll A, Heerema NA, Bowman WP, Aledo A, Slayton WB, Sather H, Devidas M, Zheng HW, Davies SM, Gaynon PS, Trigg M, Rutledge R, Jorstad D, Winick N, Borowitz MJ, Hunger SP, Carroll WL, Camitta B; Children’s Oncology Group. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031. Leukemia. 2014 Jul;28(7):1467-71. Epub 2014 Jan 20. link to original article link to PMC article EuroPMC
==Imatinib-based consolidation==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Biondi et al. 2012 (EsPhALL)	2004-2009 	Phase 3 (E-esc)	No imatinib in consolidation	Did not meet primary endpoint of DFS481
1This regimen did not meet the primary efficacy endpoint in the ITT population, but there was a possible signal in the as-treated population.
====Preceding treatment====
* Berlin–Frankfurt–Munster high-risk backbone induction
====Chemotherapy====
*Cyclophosphamide (Cytoxan) 1000 mg/m2 IV once per day on days 1 & 28
*Mercaptopurine (6-MP) 60 mg/m2 PO once per day on days 1 to 28
*Cytarabine (Ara-C) 75 mg/m2 IV or SC once per day on days 3 to 6, 10 to 13, 17 to 20, 24 to 27
====Targeted therapy====
*Imatinib (Gleevec) 300 mg/m2 PO once per day on days 1 to 28
====CNS therapy, prophylaxis====
*Methotrexate (MTX)
28-day course
====Subsequent treatment====
*Consolidation block HR1 (see paper for details)
===References===
# EsPhALL: Biondi A, Schrappe M, De Lorenzo P, Castor A, Lucchini G, Gandemer V, Pieters R, Stary J, Escherich G, Campbell M, Li CK, Vora A, Aricò M, Röttgers S, Saha V, Valsecchi MG. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. Lancet Oncol. 2012 Sep;13(9):936-45. Epub 2012 Aug 14. link to original article link to PMC article dosing details in supplement have been reviewed by our editors EuroPMC NCT00287105
Category:B-cell acute lymphoblastic leukemia regimens
Category:Biomarker-specific pages
Category:Acute lymphoblastic leukemias
Category:Pediatric hematologic neoplasms